Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
HIV Antibodies Block Infection by Reservoir-Derived Virus in Laboratory Study

The researchers conclude that passive immunotherapy involving bNAbs individually or in combination may control HIV in the absence of antiretroviral therapy. A number of clinical trials are already underway or planned to test this hypothesis.

Published
12 hours ago
From
National Institutes of Allergy and Infectious Diseases press release
Novel immune-suppressant vaccine completely blocks HIV infection in monkeys: human trials planned

A novel and relatively simple vaccine that can be administered orally has managed to completely block rectal infection with SIV, the monkey equivalent of HIV, in rhesus

Published
26 August 2014
By
Gus Cairns
Three Approaches to Beating the AIDS Epidemic in South Africa

South Africa’s AIDS epidemic is at its worst in high-risk subgroups like gay men, prostitutes, truckers, prisoners, miners and patients who don’t take their drugs regularly. To have any hope of beating the epidemic, it must focus on such groups, experts say. Many pilot projects to do that have been started with aid from the United States government program called Pepfar. Here are some of them.

Published
26 August 2014
From
New York Times
A voice for HIV cure: Scientists, activists gather for Hutch conference

Matt Sharp is no scientist. But when he joins researchers from around the country tomorrow for a conference on using gene therapy to cure HIV, he will bring a perspective that few others in the room can match.

Published
26 August 2014
From
Fred Hutchinson Cancer Research Center press release
FDA Approves New Single-Tablet HIV Regimen, Triumeq

The U.S. Food and Drug Administration (FDA) has approved Triumeq, ViiV Healthcare's single-tablet, triple-combination antiretroviral (ARV) regimen, as a first-line therapy to treat HIV. The tablet is comprised of the integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (Kivexa/Epzicom) and is the first single-tablet regimen to receive approval that does not contain tenofovir.

Published
26 August 2014
From
Aidsmeds.com
Protein tethers HIV and Ebola to cells

A family of proteins that helps viruses, such as HIV and Ebola, enter a cell also can block the release of those viruses. When HIV-1 or any virus infects a cell, it replicates and spreads to other cells. One type of cellular protein—T cell immunoglobulin and mucin domain, or TIM-1—has previously been shown to promote entry of some highly pathogenic viruses into host cells. Researchers have now discovered that the same protein possesses a unique ability to block the release of such viruses. The findings are published in the Proceedings of the National Academy of Sciences. “This is a surprising finding that provides new insights into our understanding of not only HIV infection, but also that of Ebola and other viruses,” says Shan-Lu Liu, associate professor of molecular microbiology and immunology at University of Missouri.

Published
26 August 2014
From
Futurity
The Big Picture of Small Molecules for Curing HIV Infection

Dr. David Margolis and Karine Dubé of The Martin Delaney Collaboratory of AIDS Researchers for Eradication explain one strategy being pursued by scientists as a possible way to cure HIV. After reading this, if you want to learn more check out this video on related research.

Published
22 August 2014
From
AVAC
Vault nanoparticles engineered at UCLA show promise for cancer treatment and possible HIV cure

UCLA scientists developed a method for placing bryostatin 1 in nanoscale vaults for safe delivery to cells, where it can activate latent HIV, enabling the virus to be eradicated.

Published
22 August 2014
From
UCLA press release
iCo Therapeutics Announces Positive Oral Amphotericin B Study Results

iCo Therapeutics Inc. ("iCo" or "the Company") today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs.

Published
22 August 2014
From
iCo Therapeutics press release
2000-Fold Drop in Latent Reservoir Needed for 1 Year Without ART

About a 2000-fold reduction in the HIV reservoir in resting CD4 cells may be needed to let most people stop antiretroviral therapy (ART) for a single year without rebound, according to results of a modeling study. Predicted large variations in rebound times after ART stops mean close monitoring will be required for this strategy.

Published
21 August 2014
From
International AIDS Society
← First12345...362Next →

Filter by country